Covid-19 New

More Info

Open access Aims and Scope Instructions Editorial Guidelines Licensing Copyright

Author's satisfaction with

  • Friendly and hassle-free publication process
  • Less production time of articles
  • Constructive peer-review
  • Enhancing journal reputation
  • Regular feedback system
  • Quick response to authors' queries

Read More

Recently Viewed

Environmental Factors Affecting the Concentration of DNA in Why Down-managing Backlog Forensic DNA Case Entries Matters Scintigraphic non-invasive diagnosis of amyloid cardiomyopat Anomalies of coronary artery origin: About two cases Late discover of a traumatic cardiac injury: Case report

Read More

Most Viewed

Evaluation of Biostimulants Based on Recovered Protein Hydro Sinonasal Myxoma Extending into the Orbit in a 4-Year Old: A Feasibility study of magnetic sensing for detecting single-n Physical activity can change the physiological and psycholog Pediatric Dysgerminoma: Unveiling a Rare Ovarian Tumor

Read More

Open Journals

Clinical Images

For Authors Guide For Authors Benefits For Authors Article Processing Charge How To Write a Scientific Paper How To Write a Review Article Short Communication
For Reviewers Benefits For Reviewers How To Review Thanks To Reviewers
For Editors Benefits For Editors Thanks To Editors

Abstract

Review Article

Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature

Rajib Dutta*

Published: 03 June, 2021 | Volume 5 - Issue 1 | Pages: 034-047

Medical benefits of cannabis and related compounds is widely known. Discovery of psychotropic plant cannabinoid Δ9-tetrahydrocannabinol have urged researchers to study more about the cannabinoid system and related therapeutics in the field of neurology and medicine. Where activation of cannabinoid receptor type 1 (CB1R) yielded in unwanted and serious side effects, discovery of cannabinoid receptor type 2 (CB2R) and its ligands gave a new hope. Till now there is limited success in this field because of complex expanded endocannabinoid system comprising of receptors, ligands and enzymes. In this review we will update about the role of endocannabinoidome relevant to neurological disorders.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001049 Cite this Article Read Full Article PDF

Keywords:

Cannabinoid; CB1; CB2; Receptors; Neurological disorders

References

  1. Alexander SP. Therapeutic potential of cannabis related drugs. Prog. Neuropsychopharmacol. Biol Psychiatry. 2016; 64: 157–166. PubMed: https://pubmed.ncbi.nlm.nih.gov/26216862/
  2. Plasse TF. Clinical use of dronabinol. J Clin Oncol. 2016; 9: 2079–2080. PubMed: https://pubmed.ncbi.nlm.nih.gov/1658243/b
  3. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, et al. A randomized, double- blind, placebo- controlled, parallel- group, enriched- design study of nabiximols* (Sativex®), as add- on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011; 18: 1122–1131. PubMed: https://pubmed.ncbi.nlm.nih.gov/21362108/
  4. Keating GM. Delta-9-tetrahydrocannabinol/ cannabidiol oromucosal spray (Sativex®): a review in multiple sclerosis- related spasticity. Drugs. 2017; 77: 563–574. PubMed: https://pubmed.ncbi.nlm.nih.gov/28293911/
  5. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron. 1963; 19: 2073–2078. PubMed: https://pubmed.ncbi.nlm.nih.gov/5879214/
  6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: 561–564. PubMed: https://pubmed.ncbi.nlm.nih.gov/2165569/
  7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: 61–65. PubMed: https://pubmed.ncbi.nlm.nih.gov/7689702/
  8. Maccarrone M. Missing Pieces to the Endocannabinoid Puzzle. Trends Mol Med. 2020; 26: 263-272. PubMed: https://pubmed.ncbi.nlm.nih.gov/31822395/
  9. Mazzola C, Micale V, Drago F. Amnesia induced by beta- amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol. 2003; 47: 219–225. PubMed: https://pubmed.ncbi.nlm.nih.gov/14522360/
  10. Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti GF, et al. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. J Neuropathol Exp Neurol. 2014; 73: 414–424. PubMed: https://pubmed.ncbi.nlm.nih.gov/24709676/
  11. Lunn CA. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem. 2010; 10: 768-778. PubMed: https://pubmed.ncbi.nlm.nih.gov/20370714/
  12. Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, et al. Biology and therapeutic potential of cannabinoid CB2receptor inverse agonists. Br J Pharmacol. 2008; 153: 226–239. PubMed: https://pubmed.ncbi.nlm.nih.gov/17906679/
  13. Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, et al. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Med Res Rev. 2016; 37L 441–474. PubMed: https://pubmed.ncbi.nlm.nih.gov/27879006/
  14. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nature Rev Drug Discov. 2018; 17: 623-639. PubMed: https://pubmed.ncbi.nlm.nih.gov/30116049/
  15. Sergio O, Scipioni L, Maccarrone M. Endocannabinoid system and adult neurogenesis: a focused review. Curr Opinion Pharmacol. 2020; 50: 25-32.
  16. Arturo IF, Fabiana P. Endocannabinoidome. 2018.
  17. Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103: 61–101. PubMed: https://pubmed.ncbi.nlm.nih.gov/28120231/
  18. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, et al. Cannabidiol in patients with treatment- resistant epilepsy: an open- label interventional trial. Lancet Neurol. 2016; 15: 270–278. PubMed: https://pubmed.ncbi.nlm.nih.gov/26724101/
  19. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, et al. Trial of cannabidiol for drug resistant seizures in the Dravet syndrome. N Engl J Med. 2017; 376: 2011–2020. PubMed: https://pubmed.ncbi.nlm.nih.gov/28538134/
  20. Benito C, Tolón RM, Castillo AI, Ruiz-Valdepeñas L, Martínez-Orgado JA, et al. beta- Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR- alpha, PPAR- gamma and TRPV1, but not CB(1) or CB(2) receptors. Br J Pharmacol. 2012; 166: 1474–1489. PubMed: https://pubmed.ncbi.nlm.nih.gov/22321194/
  21. Luchicchi A, Lecca S, Carta S, Pillolla G, Muntoni AL, et al. Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR- alpha nuclear receptors. Addict Biol. 2010; 15: 277–288. PubMed: https://pubmed.ncbi.nlm.nih.gov/20477753/
  22. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW, et al. GPR119 as a fat sensor. Trends Pharmacol Sci. 2012; 33: 374–381. PubMed: https://pubmed.ncbi.nlm.nih.gov/22560300/
  23. Kawahara H, Drew GM, Christie MJ, Vaughan CW. Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br J Pharmacol. 2011; 163: 1214–1222. PubMed: https://pubmed.ncbi.nlm.nih.gov/21175570/
  24. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011; 18: 846–856. PubMed: https://pubmed.ncbi.nlm.nih.gov/21802006/
  25. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, et al. A dysregulated endocannabinoid eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell Rep. 2012; 1: 617–623. PubMed: https://pubmed.ncbi.nlm.nih.gov/22813736/
  26. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progr Lipid Res. 2016; 62: 107–128. PubMed: https://pubmed.ncbi.nlm.nih.gov/26965148/
  27. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008; 14: 923–930. PubMed: https://pubmed.ncbi.nlm.nih.gov/18776886/
  28. Matyas F, Urbán GM, Watanabe M, Mackie K, Zimmer A, et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology. 2008; 54: 95–107. PubMed: https://pubmed.ncbi.nlm.nih.gov/17655884/
  29. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001; 410: 588–592. PubMed: https://pubmed.ncbi.nlm.nih.gov/11279497/
  30. Marinelli S, Pacioni S, Bisogno T, Di Marzo V, Prince DA, et al. The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self- inhibition in neocortical interneurons. J Neurosci. 2008; 28: 13532–13541. PubMed: https://pubmed.ncbi.nlm.nih.gov/19074027/
  31. Benard G, Massa F, Puente N, Lourenço J, Bellocchio L, et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci. 2012; 15: 558–564. PubMed: https://pubmed.ncbi.nlm.nih.gov/22388959/
  32. Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, et al. A cannabinoid link between mitochondria and memory. Nature. 2016; 539: 555–559. PubMed: https://pubmed.ncbi.nlm.nih.gov/27828947/
  33. Prenderville JA, Kelly ÁM, Downer EJ. The role of cannabinoids in adult neurogenesis. Br J Pharmacol. 2015; 172: 3950–3963. PubMed: https://pubmed.ncbi.nlm.nih.gov/25951750/
  34. Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, et al. Cannabinoid pharmacology/ therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol. 2018; 157: 67–84. PubMed: https://pubmed.ncbi.nlm.nih.gov/30121249/
  35. Palazuelos J, Ortega Z, Díaz-Alonso J, Guzmán M, Galve-Roperh I. CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling. J Biol Chem. 2012; 287: 1198–1209. PubMed: https://pubmed.ncbi.nlm.nih.gov/22102284/
  36. Chung YC, Shin WO, Baek JY, Cho EJ, Baik HH, et al. CB2 receptor activation prevents glial- derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease. Exp Mol Med. 2016; 48: e205. PubMed: https://pubmed.ncbi.nlm.nih.gov/27534533/
  37. Marchalant Y, Brownjohn PW, Bonnet A, Kleffmann T, Ashton JC. Validating antibodies to the cannabinoid CB2 receptor: antibody sensitivity is not evidence of antibody specificity. J Histochem Cytochem. 2014; 62: 395–404. PubMed: https://pubmed.ncbi.nlm.nih.gov/24670796/
  38. Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off- target activity. Nat Commun. 2017; 8: 13958. PubMed: https://pubmed.ncbi.nlm.nih.gov/28045021/
  39. Stempel AV, Stumpf A, Zhang HY, Özdoğan T, Pannasch U, et al. Cannabinoid type 2 receptors mediate a cell type- specific plasticity in the hippocampus. Neuron. 2016; 90: 795–809. PubMed: https://pubmed.ncbi.nlm.nih.gov/27133464/
  40. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, et al. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006; 139: 1405–1415. PubMed: https://pubmed.ncbi.nlm.nih.gov/16603318/
  41. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience. 2008; 151: 955–968. PubMed: https://pubmed.ncbi.nlm.nih.gov/18248904/
  42. Villapol S. Roles of peroxisome proliferator activated receptor gamma on brain and peripheral inflammation. Cell Mol. Neurobiol. 2018; 38: 121–132. PubMed: https://pubmed.ncbi.nlm.nih.gov/28975471/
  43. Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid- and lysophosphatidyl inositol- sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci. USA. 2013; 110: 5193–5198. PubMed: https://pubmed.ncbi.nlm.nih.gov/23472002/
  44. McHugh D, Wager-Miller J, Page J, Bradshaw HB. siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N- arachidonoyl glycine- induced cell migration. J Mol Signal. 2012; 7: 10. PubMed: https://pubmed.ncbi.nlm.nih.gov/22834922/
  45. Crivelaro do Nascimento G, Ferrari DP, Guimaraes FS, Del Bel EA, Bortolanza M, et al. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson’s disease. Neuropharmacology. 2019; 163: 107808. PubMed: https://pubmed.ncbi.nlm.nih.gov/31706993/
  46. Davis MP, Behm B, Mehta Z, Fernandez C. The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. Am J Hosp Palliat Med. 2019; 36: 1134-1154. PubMed: https://pubmed.ncbi.nlm.nih.gov/31113223/
  47. Martínez-Pinilla E, Aguinaga D, Navarro G, Rico AJ, Oyarzábal J, et al. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease. Mole Neurobiol. 2019; 56: 5900-5910. PubMed: https://pubmed.ncbi.nlm.nih.gov/30687889/
  48. Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double- blind trial. J Psychopharmacol. 2014; 28: 1088–1098. PubMed: https://pubmed.ncbi.nlm.nih.gov/25237116/
  49. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, et al. Cannabinoids reduce levodopa induced dyskinesia in Parkinson’s disease: a pilot study. Neurology. 2001; 57: 2108–2111. PubMed: https://pubmed.ncbi.nlm.nih.gov/11739835/
  50. Brotini S, Schievano C, Guidi L. Ultramicronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017; 16: 705–713. PubMed: https://pubmed.ncbi.nlm.nih.gov/28325153/
  51. Ruthirakuhan M, Herrmann N, Andreazza AC, Verhoeff NP, Gallagher D, et al. Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. J Geriatric Psychiatry Neurol. 2019; 2020; 33: 175-184. PubMed: https://pubmed.ncbi.nlm.nih.gov/31547752/
  52. Franco R, Reyes‐Resina I, Aguinaga D, Lillo A, Jiménez J, Raïch I, et al. Potentiation of cannabinoid signaling in microglia by adenosine A 2A receptor antagonists. Glia. 2019; 67: 2410-2423. PubMed: https://pubmed.ncbi.nlm.nih.gov/31429130/
  53. Montanari S, Mahmoud AM, Pruccoli L, Rabbito A, Naldi M, et al. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer’s disease treatment. Eur J Med Chem. 2019. PubMed: https://pubmed.ncbi.nlm.nih.gov/31185414/
  54. Balleza-Tapia H, Crux S, Andrade-Talavera Y, Dolz-Gaiton P, Papadia D, et al. TrpV1 receptor activation rescues neuronal function and network gamma oscillations from Aβ-induced impairment in mouse hippocampus in vitro. Elife, 2018; 7: e37703. PubMed: https://pubmed.ncbi.nlm.nih.gov/30417826/
  55. Aparicio N, Grande MT, Ruiz de Martín Esteban S, López A, Ruiz-Pérez G, et al. Role of Interleukin 1-Beta In The Inflammatory Response In A Fatty Acid Amide Hydrolase-Knockout Mouse Model of Alzheimer’s Disease. Biochem Pharmacol. 2018; 157: 202-209. PubMed: https://pubmed.ncbi.nlm.nih.gov/30195729/
  56. Talarico G, Trebbastoni A, Bruno G, de Lena C. Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease. Curr Neuropharmacol. 2019; 17: 176-183. PubMed: https://pubmed.ncbi.nlm.nih.gov/29962346/
  57. Takkinen JS, López-Picón FR, Kirjavainen AK, Pihlaja R, Snellman A, et al. 18 F]FMPEP- d 2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2018; 69: 199–208. PubMed: https://pubmed.ncbi.nlm.nih.gov/29909177/
  58. Schmöle AC, Lundt R, Toporowski G, Hansen JN, Beins E, et al. Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer’s Disease-Like Pathology. J Alzheimers Dis. 2018; 64: 379–392. PubMed: https://pubmed.ncbi.nlm.nih.gov/29865078/
  59. Llorente-Ovejero A, Manuel I, Lombardero L, Giralt MT, Ledent C, et al. Endocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer’s Disease. J Alzheimers Dis. 2018; 64: 117–136. PubMed: https://pubmed.ncbi.nlm.nih.gov/29865071/
  60. Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia- related agitation. Int J Geriatr Psychiatry. 2008; 23: 116–117. PubMed: https://pubmed.ncbi.nlm.nih.gov/18081000/
  61. van den Elsen GAH. Ahmed AIA, Verkes RJ, Kramers C, Feuth T, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015; 84: 2338–2346. PubMed: https://pubmed.ncbi.nlm.nih.gov/25972490/
  62. van den Elsen GAH, Ahmed AIA, Verkes RJ, Feuth T, van der Marck MA. et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015; 23: 1214–1224. PubMed: https://pubmed.ncbi.nlm.nih.gov/26560511/
  63. van den Elsen GAH, Tobben L, Ahmed AI, Verkes RJ, Kramers C, et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial. J Psychopharmacol. 2017; 31: 184–191. PubMed: https://pubmed.ncbi.nlm.nih.gov/27624148/
  64. Smith‐Dijak AI, Sepers MD, Raymond LA. Alterations in Synaptic Function and Plasticity in Huntington Disease. J Neurochem. 2019; 150: 346-365. PubMed: https://pubmed.ncbi.nlm.nih.gov/31095731/
  65. Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, et al. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington’s disease in the R6/2 mouse model. Neuropharmacology. 2019; 151: 1-12. PubMed: https://pubmed.ncbi.nlm.nih.gov/30940536/
  66. Covey DP, Dantrassy HM, Yohn SE, Castro A, Conn PJ, et al. Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease. Neuropsychopharmacology. 2018; 43: 2056–2063. PubMed: https://pubmed.ncbi.nlm.nih.gov/29925886/
  67. Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington’s Disease. Methods Mol Biol. 2018; 549–571. PubMed: https://pubmed.ncbi.nlm.nih.gov/29856035/
  68. Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, et al. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington’s Disease Mouse Model. J Neurosci. 2017; 38: 544–554. PubMed: https://pubmed.ncbi.nlm.nih.gov/29192125/
  69. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-Lévi AC, Zuccato C, et al. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington’s disease mutation in peripheral lymphocytes. Neurobiol Dis. 2007; 27: 108–116. PubMed: https://pubmed.ncbi.nlm.nih.gov/17553686/
  70. Lopez-Sendon M, Caldentey JC, Cubillo PT, Romero CR, Ribas GG, et al. A double- blind, randomized, cross- over, placebo- controlled, pilot trialwith Sativex in Huntington’s disease. J Neurol. 2016; 263: 1390–1400. PubMed: https://pubmed.ncbi.nlm.nih.gov/27159993/
  71. Saft C, von Hein SM, Lücke T, Thiels C, Peball M, et al. Cannabinoids for treatment of dystonia in Huntington’s disease. J Huntingt Dis. 2018; 7: 167–173. PubMed: https://pubmed.ncbi.nlm.nih.gov/29562549/
  72. Consroe P, Laguna J, Allender J, Snider S, Stern L, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991; 40: 701–708. PubMed: https://pubmed.ncbi.nlm.nih.gov/1839644/
  73. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord. 2009; 24: 2254–2259. PubMed: https://pubmed.ncbi.nlm.nih.gov/19845035/
  74. Armstrong MJ, Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012; 79: 597–603. PubMed: https://pubmed.ncbi.nlm.nih.gov/22815556/
  75. Curtis A, Rickards H. Nabilone Could Treat Chorea and Irritability in Huntington’s Disease. J Neuropsychiatry Clin Neurosci. 2006; 18: 553–554. PubMed: https://pubmed.ncbi.nlm.nih.gov/17135385/
  76. Muller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington’s disease. Mov Disord. 1999; 14: 1038–1040. PubMed: https://pubmed.ncbi.nlm.nih.gov/10584686/
  77. Eger M, Bader M, Bree D, Hadar R, Nemerovski A, et al. Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury is Mediated by the Cannabinoid-1 Receptor. Sci Rep. 2019; 9: 16196. PubMed: https://pubmed.ncbi.nlm.nih.gov/31700010/
  78. Honn KV, Zeldin DC. The Role of Bioactive Lipids in Cancer, Inflammation and Related Diseases. Adv Experimen Med Biol. 2019.
  79. Fucich EA, Mayeux JP, McGinn MA, Gilpin NW, Edwards S, et al. A Novel Role for the Endocannabinoid System in Ameliorating Motivation for Alcohol Drinking and Negative Behavioral Affect Following Traumatic Brain Injury in Rats. J Neurotrauma. 2019; : 36: 1847-1855. PubMed: https://pubmed.ncbi.nlm.nih.gov/30638118/
  80. Xu X, Jiang S, Xu E, Wu X, Zhao R. Inhibition of CB1 receptor ameliorates spatial learning and memory impairment in mice with traumatic brain injury. Neurosci Lett. 2019; 696: 127-131. PubMed: https://pubmed.ncbi.nlm.nih.gov/30576711/
  81. Magid L, Heymann S, Elgali M, Avram L, Cohen Y, et al. The Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury. J Neurotrauma. 2018; 36: 1836-1846. PubMed: https://pubmed.ncbi.nlm.nih.gov/30489198/
  82. Piro JR, Suidan GL, Quan J, Pi Y, O’Neill SM, et al. Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. J Neuroinflammation. 2018; 15.
  83. Braun M, Khan ZT, Khan MB, Kumar M, Ward A, et al. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun. 2017; 68: 224–237. PubMed: https://pubmed.ncbi.nlm.nih.gov/29079445/
  84. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001; 413: 527–531. PubMed: https://pubmed.ncbi.nlm.nih.gov/11586361/
  85. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, et al. The endocannabinoid 2-AG protects the blood- brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006; 22: 257–264. PubMed: https://pubmed.ncbi.nlm.nih.gov/16364651/
  86. Mayeux J, Katz P, Edwards S, Middleton JW, Molina PE, et al. Inhibition of endocannabinoid degradation improves outcomes from mild traumatic brain injury: a mechanistic role for synaptic hyperexcitability. J Neurotrauma. 2017; 34: 436–443. PubMed: https://pubmed.ncbi.nlm.nih.gov/27189876/
  87. Katz PS, Sulzer JK, Impastato RA, Teng SX, Rogers EK, et al. Endocannabinoid degradation inhibition improves neurobehavioral function, bloodbrain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma. 2015; 32: 297–306. PubMed: https://pubmed.ncbi.nlm.nih.gov/25166905/
  88. Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, et al. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after Traumatic brain injury in mice. Brain Behav. Immun. 2012; 26: 1310–1321. PubMed: https://pubmed.ncbi.nlm.nih.gov/22884901/
  89. Cohen- Yeshurun A, Willner D, Trembovler V, Alexandrovich A, Mechoulam R, et al. N- arachidonoyl-L- serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab. 2013; 33: 1242–1250. PubMed: https://pubmed.ncbi.nlm.nih.gov/23695434/
  90. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci. USA. 1989; 86: 9584–9587. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC298542/
  91. Maas AI, Murray G, Henney H, Kassem N, Legrand V, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo- controlled, clinical trial. Lancet Neurol. 2006; 5: 38–45. PubMed: https://pubmed.ncbi.nlm.nih.gov/16361021/
  92. Laila A, Iglesias LP, De Oliveira AC, Moraes MFD, Moreira FA. Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. Epilepsy Behavior. 2019; 106832. PubMed: https://pubmed.ncbi.nlm.nih.gov/31839498/
  93. Cheung KAK, Peiris H, Wallace G, Holland OJ, Mitchell MD. The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. Int J Mole Sci. 2019; 20: 6079. PubMed: https://pubmed.ncbi.nlm.nih.gov/31810321/
  94. Shapiro L, Wong JC, Escayg A. Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice. Epilepsia. 2019; 60: 2359-2369. PubMed: https://pubmed.ncbi.nlm.nih.gov/31758544/
  95. Vinogradova LV, van Rijn CM. Long- term disease- modifying effect of the endocannabinoid agonist WIN55,212-2 in a rat model of audiogenic epilepsy. Pharmacol Rep. 2015; 67: 501–503. PubMed: https://pubmed.ncbi.nlm.nih.gov/25933961/
  96. Di Maio R, Cannon JR, Greenamyre JT. Poststatus epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats. Neurobiol Dis. 2015; 73: 356–365. PubMed: https://pubmed.ncbi.nlm.nih.gov/25447228/
  97. Bhaskaran MD, Smith BN. Cannabinoid mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. Plos One. 2010; 5: e10683. PubMed: https://pubmed.ncbi.nlm.nih.gov/20498848/
  98. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003; 307: 129–137. PubMed: https://pubmed.ncbi.nlm.nih.gov/12954810/
  99. Vinogradova LV, Shatskova AB, van Rijn CM. Pro- epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy. Epilepsy Res. 2011; 96: 250–256. PubMed: https://pubmed.ncbi.nlm.nih.gov/21733658/
  100. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. CB1 cannabinoid receptors and on- demand defense against excitotoxicity. Science. 2003; 302: 84–88. PubMed: https://pubmed.ncbi.nlm.nih.gov/14526074/
  101. Vilela LR, Medeiros DC, Rezende GHS, de Oliveira ACP, Moraes MFD, et al. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole- induced seizure and electroencephalographic activity in rats. Epilepsy Res. 2013; 104; 195–202. PubMed: https://pubmed.ncbi.nlm.nih.gov/23352737/
  102. Shubina L, Aliev R, Kitchigina V. Attenuation of kainic acid- induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. Epilepsy Res. 2015; 111: 33–44. PubMed: https://pubmed.ncbi.nlm.nih.gov/25769371/
  103. Jones NA, Hill AJ, Smith J, Bevan SA, Williams CM, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010; 332: 569–577. PubMed: https://pubmed.ncbi.nlm.nih.gov/19906779/
  104. Jones NA, Glyn SE, Akiyama S, Hill TDM, Hill AJ, et al. Cannabidiol exerts anti- convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012; 21: 344–352. PubMed: https://pubmed.ncbi.nlm.nih.gov/22520455/
  105. Khan AA, Shekh-Ahmad T, Khalil A, Walker MC, Ali AA, et al. Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model. Br J Pharmacol. 2018; 175: 2097–2115. PubMed: https://pubmed.ncbi.nlm.nih.gov/29574880/
  106. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, et al. Cannabidiol in patients with seizures associated with Lennox- Gastaut syndrome (GWPCARE4): a randomised, double- blind, placebo-controlled phase 3 trial. Lancet. 2018; 391: 1085–1096. PubMed: https://pubmed.ncbi.nlm.nih.gov/29395273/
  107. Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, et al. Open- label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018; 86: 131–137. PubMed: https://pubmed.ncbi.nlm.nih.gov/30006259/
  108. Gofshteyn JS. Cannabidiol as a potential treatment for febrile infection- related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017; 32: 35–40. PubMed: https://pubmed.ncbi.nlm.nih.gov/27655472/
  109. Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P. Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2017; 29: 391–400. PubMed: https://pubmed.ncbi.nlm.nih.gov/28464701/
  110. Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry. 1999; 156: 495. PubMed: https://pubmed.ncbi.nlm.nih.gov/10080574/
  111. Muller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013; 27: 119–124. PubMed: https://pubmed.ncbi.nlm.nih.gov/23187140/
  112. Kanaan A, Jakubovski E, Müller-Vahl K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017; 7: 47. PubMed: https://pubmed.ncbi.nlm.nih.gov/28445405/
  113. Jiang M, van der Stelt M. Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders. J Med Chem. 2018; 61: 9059-9061. PubMed: https://pubmed.ncbi.nlm.nih.gov/30354159/
  114. Hohmann U, Pelzer M, Kleine J, Hohmann T, Ghadban C, et al. Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2-Arachidonoylglycerol on Function and Morphology of Microglia. Front Neurosci. 2019; 13: 1180. PubMed: https://pubmed.ncbi.nlm.nih.gov/31787870/
  115. Rajah G, Kolb B, Saber H, Fadel H. The endocannabinoid system and stroke: A focused review. Brain Circulation. 2019; 5: 1-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/31001593/
  116. Luo D, Zhang Y, Yuan X, Pan Y, Yang L, et al. Oleoylethanolamide inhibits glial activation via moudulating PPARα and promotes motor function recovery after brain ischemia. Pharmacological Res. 2019; 141: 530-540. PubMed: https://pubmed.ncbi.nlm.nih.gov/30660821/
  117. Yang X, Xu L, Zhou J, Ge Y, Wu S, et al. Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy. J Nanobiotechnol. 2019; 17: 8. PubMed: https://pubmed.ncbi.nlm.nih.gov/30660200/
  118. Zhou J, Noori H, Burkovskiy I, Lafreniere J, Kelly M, et al. Modulation of the Endocannabinoid System Following Central Nervous System Injury. Int J Mole Sci. 2019; 20: 388. PubMed: https://pubmed.ncbi.nlm.nih.gov/30658442/
  119. Ilyasov AA, Milligan CE, Pharr EP, Howlett AC. The Endocannabinoid System and Oligodendrocytes in Health and Disease. Front Neurosci. 2018; 12; 733. PubMed: https://pubmed.ncbi.nlm.nih.gov/30416422/
  120. Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Molecular Brain. 2018; 11: 51. PubMed: https://pubmed.ncbi.nlm.nih.gov/30223868/
  121. Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, et al. Cannabinoid signalling in the immature brain: encephalopathies and neurodevelopmental disorders. Biochem Pharmacol. 2018; 157: 85-96. PubMed: https://pubmed.ncbi.nlm.nih.gov/30118663/
  122. Holubiec MI, Romero JI, Suárez J, Portavella M, Fernández-Espejo E, et al. Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia. Psychopharmacology. 2018; 235: 2929-2945. PubMed: https://pubmed.ncbi.nlm.nih.gov/30058012/
  123. Chi OZ, Barsoum S, Grayson J, Hunter C, Liu X, et al. Effects of cannabinoid receptor agonist WIN 55,212-2 on blood- brain barrier disruption in focal cerebral ischemia in rats. Pharmacology. 2012; 89: 333–338. PubMed: https://pubmed.ncbi.nlm.nih.gov/22678129/
  124. Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E. Neuroprotective and brain edema reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res. 2003; 989: 99–111. PubMed: https://pubmed.ncbi.nlm.nih.gov/14519516/
  125. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Ogata A, et al. Delta 9-tetrahydrocannabinol (delta9-THC) prevents cerebral infarction via hypothalamic- independent hypothermia. Life Sci. 2007; 80: 1466–1471. PubMed: https://pubmed.ncbi.nlm.nih.gov/17289082/
  126. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock- out mice. J Neurosci. 2002; 22: 9771–9775. PubMed: https://pubmed.ncbi.nlm.nih.gov/12427832/
  127. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience. 2004; 129: 743–750. PubMed: https://pubmed.ncbi.nlm.nih.gov/15541895/
  128. Zarruk JG, Fernández-López D, García-Yébenes I, García-Gutiérrez MS, Vivancos J, et al. Cannabinoid type 2 receptor activation downregulates stroke- induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke. 2012; 43: 211–219. PubMed: https://pubmed.ncbi.nlm.nih.gov/22020035/
  129. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, et al. CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/ reperfusion injury. Microvasc Res. 2009; 78: 86–94. PubMed: https://pubmed.ncbi.nlm.nih.gov/19332079/
  130. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxicischemic newborn piglets. Pediatr Res. 2008; 64: 653–658. PubMed: https://pubmed.ncbi.nlm.nih.gov/18679164/
  131. Lafuente H, Alvarez FJ, Pazos MR, Alvarez A, Rey-Santano MC, et al. Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia ischemia in newborn pigs. Pediatr Res. 2011; 70; 272–277. PubMed: https://pubmed.ncbi.nlm.nih.gov/21654550/
  132. Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxicischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis. 2010; 37: 434–440. PubMed: https://pubmed.ncbi.nlm.nih.gov/19900555/
  133. Marinelli L, Maurizio Balestrino, Laura Mori, Luca Puce, Gian Marco Rosa, et al. A randomised controlled cross- over double- blind pilot study protocol on THC: CBD oromucosal spray efficacy as an add- on therapy for post- stroke spasticity. BMJ Open. 2017; 7: e016843. PubMed: https://pubmed.ncbi.nlm.nih.gov/28882919/
  134. Caltagirone C, Carlo Cisari, Carlo Schievano, Rosanna Di Paola, Marika Cordaro, et al. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016; 7: 54-69. PubMed: https://pubmed.ncbi.nlm.nih.gov/26706245/
  135. Espejo-Porras F, Fernández-Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotrophic Lateral Scler Frontotemporal Degener. 2018; 19: 377-386. PubMed: https://pubmed.ncbi.nlm.nih.gov/29334787/
  136. Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology. 2017; 124: 157-169. PubMed: https://pubmed.ncbi.nlm.nih.gov/28373073/
  137. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates JR, Pérez-Díaz C, et al. Upregulation of CB2receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech. 2017; 10: 551-558. PubMed: https://pubmed.ncbi.nlm.nih.gov/28069688/
  138. Zhao P, Ignacio S, Beattie EC, Abood ME. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci. 2008; 27: 572-579. PubMed: https://pubmed.ncbi.nlm.nih.gov/18279310/
  139. Shoemaker JL, Kathryn A Seely, Ronald L Reed, John P Crow, Paul L Prather. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007; 101: 87-98. PubMed: https://pubmed.ncbi.nlm.nih.gov/17241118/
  140. Espejo- Porras F, Fabiana Piscitelli, Roberta Verde, José A Ramos, Vincenzo Di Marzo, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol. 2015; 10: 233-244. PubMed: https://pubmed.ncbi.nlm.nih.gov/25819934/
  141. Espejo- Porras F, Fernandez- Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post- mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19: 377-386. PubMed: https://pubmed.ncbi.nlm.nih.gov/29334787/
  142. Witting A, Patrick Weydt, Soyon Hong, Michel Kliot, Thomas Moller, et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem. 2004; 89: 1555-1557. PubMed: https://pubmed.ncbi.nlm.nih.gov/15189359/
  143. Bilsland LG, James RT Dick, Pryce G, Petrosino S, Di Marzo V, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006; 20: 1003–1005. PubMed: https://pubmed.ncbi.nlm.nih.gov/16571781/
  144. Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology. 2017; 124: 157-169. PubMed: https://pubmed.ncbi.nlm.nih.gov/28373073/
  145. Rajan TS, Scionti D, Diomede F, Grassi G, Pollastro F, et al. Gingival stromal cells as an in vitro model: cannabidiol modulates genes linked with amyotrophic lateral sclerosis. J Cell Biochem. 2017; 118: 819-828. PubMed: https://pubmed.ncbi.nlm.nih.gov/27714895/
  146. Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014; 20: 809-815. PubMed: https://pubmed.ncbi.nlm.nih.gov/24703394/
  147. Palma E, Reyes-Ruiz JM, Lopergolo D, Roseti C, Bertollini C, et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci USA. 2016; 113: 3060-3065. PubMed: https://pubmed.ncbi.nlm.nih.gov/26929355/
  148. Clemente S. Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report. CNS Neurol Disord Drug Targets. 2012; 11: 933-936. PubMed: https://pubmed.ncbi.nlm.nih.gov/22998138/
  149. Stampanoni Bassi M, Gentile A, Iezzi E, Zagaglia S, Musella A, et al. Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis. Front Neurol. 2019; 10: 30. PubMed: https://pubmed.ncbi.nlm.nih.gov/30761069/
  150. Mecha M, Yanguas-Casás N, Feliú AA, Mestre L, Carrillo-Salinas F, et al. The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia. Brain, Behav Immun. 2019; 77: 110-126. PubMed: https://pubmed.ncbi.nlm.nih.gov/30582962/
  151. Baker D, G Pryce, J L Croxford, P Brown, R G Pertwee, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000; 404: 84-87. PubMed: https://pubmed.ncbi.nlm.nih.gov/10716447/
  152. Baker D, G Pryce, J L Croxford, P Brown, R G Pertwee, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001; 15: 300-302. PubMed: https://pubmed.ncbi.nlm.nih.gov/11156943/
  153. Hilliard A, C Stott, S Wright, G Guy, G Pryce, et al. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. ISRN Neurol. 2012; 2012: 802649. PubMed: https://pubmed.ncbi.nlm.nih.gov/22928118/
  154. Giacoppo S, Bramanti P, Mazzon E. Sativex in the management of multiple sclerosis- related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord. 2017; 17: 22-31. PubMed: https://pubmed.ncbi.nlm.nih.gov/29055461/
  155. Markova J, Ute Essner, Bülent Akmaz, Marcella Marinelli, Christiane Trompke, et al. Sativex® as add- on therapy vs. further optimized first- line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double- blind, placebo- controlled randomised clinical trial. Int J Neurosci. 2018; 129: 119-128. PubMed: https://pubmed.ncbi.nlm.nih.gov/29792372/
  156. Koch G, Francesco Mori, Claudia Codecà, Hajime Kusayanagi, Fabrizia Monteleone, et al. Cannabis- based treatment induces polarity- reversing plasticity assessed by theta burst stimulation in humans. Brain Stimul. 2009; 2: 229-233. PubMed: https://pubmed.ncbi.nlm.nih.gov/20633421/
  157. Carotenuto A, Iodice R, Petracca M, Inglese M, Cerillo I, et al. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®. Acta Neurol Scand. 2017; 135: 442-448. PubMed: https://pubmed.ncbi.nlm.nih.gov/27500463/
  158. Russo M, Calabrò RS, Naro A, Sessa E, Rifici C, et al. Sativex in the management of multiple sclerosis- related spasticity: role of the corticospinal modulation. Neural Plast. 2015; 2015: 656582. PubMed: https://pubmed.ncbi.nlm.nih.gov/25699191/
  159. Turri M, Francesco T, Francesco D, Giampietro Z, Valeria T, et al. Pain modulation after oromucosal cannabinoid spray (SATIVEX®) in patients with multiple sclerosis: a study with quantitative sensory testing and laser- evoked potentials. Medicines. 2018; 5: 59. PubMed: https://pubmed.ncbi.nlm.nih.gov/29933552/
  160. Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, et al. Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLOS ONE. 2017; 12: PubMed: https://pubmed.ncbi.nlm.nih.gov/28763462/
  161. Sorosina M, Clarelli F, Ferrè L, Osiceanu AM , Unal NT, et al. Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018; 25: 934–e70. PubMed: https://pubmed.ncbi.nlm.nih.gov/29528549/
  162. Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon- beta1a and circulating proinflammatory cytokines in relapsing- remitting multiple sclerosis. Neurotherapeutics. 2016; 13: 428-438. PubMed: https://pubmed.ncbi.nlm.nih.gov/26857391/
  163. Galve-Roperh I, Sánchez C, Cortés ML, del Pulgar TD, Izquierdo M, et al. Anti- tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal- regulated kinase activation. Nat Med. 2000; 6: 313-319. PubMed: https://pubmed.ncbi.nlm.nih.gov/10700234/
  164. Blazquez C, M Llanos Casanova, Anna Planas, Teresa Gómez Del Pulgar, Concepción Villanueva, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003; 17: 529-531. PubMed: https://pubmed.ncbi.nlm.nih.gov/12514108/
  165. Gurley SN, Ammaar H Abidi, Patrick Allison, Peihong Guan, Christopher Duntsch, et al. Mechanism of anti- glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. J Neurooncol. 2012; 110: 163-177. PubMed: https://pubmed.ncbi.nlm.nih.gov/22875710/
  166. Sanchez C, M L de Ceballos, T Gomez del Pulgar, D Rueda, C Corbacho, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001; 61: 5784-5789. PubMed: https://pubmed.ncbi.nlm.nih.gov/11479216/
  167. Aguado T, Arkaitz Carracedo, Boris Julien, Guillermo Velasco, Garry Milman, et al. Cannabinoids induce glioma stem- like cell differentiation and inhibit gliomagenesis. J Biol Chem. 2007; 282: 6854-6862. PubMed: https://pubmed.ncbi.nlm.nih.gov/17202146/
  168. Chao Ma, Ting-Ting Wu, Pu-Cha Jiang, Zhi-Qiang Li, Xin-Jun Chen, et al. Anti- carcinogenic activity of anandamide on human glioma in vitro and in vivo. Mol Med Rep. 2016; 13: 1558-1562. PubMed: https://pubmed.ncbi.nlm.nih.gov/26707955/
  169. Massimo Nabissi, Maria Beatrice Morelli, Antonietta Arcella, Claudio Cardinali, Matteo Santoni, et al. Post- transcriptional regulation of5′-untranslated regions of human transient receptor potential vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. Oncotarget. 2016; 7: 81541–81554. PubMed: https://pubmed.ncbi.nlm.nih.gov/27829230/
  170. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor independent mechanism. Br J Pharmacol. 2005; 144: 1032-1036. PubMed: https://pubmed.ncbi.nlm.nih.gov/15700028/
  171. Moreno E, Clara A, Mireia M, María M C, Eduardo Pérez-Gómez, et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem. 2014; 289: 21960-21972. PubMed: https://pubmed.ncbi.nlm.nih.gov/24942731/
  172. Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and delta9- tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 13, 2955-2967. PubMed: https://pubmed.ncbi.nlm.nih.gov/25398831/
  173. Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011; 10: 90-103. PubMed: https://pubmed.ncbi.nlm.nih.gov/21220494/
  174. Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2013; 34: 48–57. PubMed: https://pubmed.ncbi.nlm.nih.gov/23079154/
  175. Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, et al. Cannabidiol stimulates Aml-1adependent glial differentiation and inhibits glioma stem- like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer. 2015; 137: 1855-1869. PubMed: https://pubmed.ncbi.nlm.nih.gov/25903924/
  176. Sugimoto N, Ishibashi H, Ueda Y, Nakamura H, Yachie A, et al. Corticosterone inhibits the expression of cannabinoid receptor‑1 and cannabinoid receptor agonist‑induced decrease in cell viability in glioblastoma cells. Oncol Lett. 2019; 18: 1557-1563. PubMed: https://pubmed.ncbi.nlm.nih.gov/31423223/
  177. Fu H, Ge B, Chen D, Wu Y, Luo Q, et al. Phytanoyl-CoA 2-Hydroxylase-Interacting Protein-Like Gene Is a Therapeutic Target Gene for Glioblastoma Multiforme. Med Sci Monit. 2019; 25: 2583-2590. PubMed: https://pubmed.ncbi.nlm.nih.gov/30962415/
  178. Su B-X, Chen X, Huo J, Guo S.-Y, Ma R, et al. The synthetic cannabinoid WIN55212-2 ameliorates traumatic spinal cord injury via inhibition of GAPDH/Siah1 in a CB2-receptor dependent manner. Brain Res. 2017; 1671: 85–92. PubMed: https://pubmed.ncbi.nlm.nih.gov/28716633/
  179. Milligan AL, Szabo-Pardi TA, Burton MD. Cannabinoid Receptor Type 1 and Its Role as an Analgesic: An Opioid Alternative? J Dual Diagn. 2019; 16: 106-119. PubMed: https://pubmed.ncbi.nlm.nih.gov/31596190/
  180. Haggai S, Brill S. Cannabis-based medicines for chronic pain management: current and future prospects. Curr Opin Anesthesiol. 2019; 32: 623-628. PubMed: https://pubmed.ncbi.nlm.nih.gov/31356363/
  181. Blanton HL, Brelsfoard J, DeTurk N, Pruitt K, Narasimhan M, et al. Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. Drugs. 2019; 79: 969-995. PubMed: https://pubmed.ncbi.nlm.nih.gov/31127530/
  182. Henshaw FR, Dewsbury LS, Lim CK, Steiner GZ. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. Cannabis Cannabinoid Res. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/33998900/
  183. Haranishi Y, Hara K, Terada T. Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. Pharmacol Rep. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/33783763/
  184. Armin S, Muenster S, Abood M, Benamar K. GPR55 in the brain and chronic neuropathic pain. Behav Brain Res. 2021; 406: 113248. PubMed: https://pubmed.ncbi.nlm.nih.gov/33745983/
  185. Canavan C, Inoue T, McMahon S, Doody C, Blake C, et al. The Efficacy, Adverse Events & Withdrawal Rates of the Pharmacological Management of Chronic Spinal Cord Injury Pain: A Systematic Review & Meta-Analysis. Pain Med. 2021; pnab140. PubMed: https://pubmed.ncbi.nlm.nih.gov/33844010/
  186. Nabata KJ, Tse EK, Nightingale TE, Lee AHX, Eng JJ, et al. The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review. Curr Neuropharmacol. 2021; 19: 402-432. PubMed: https://pubmed.ncbi.nlm.nih.gov/32310048/
  187. Jing N, Fang B, Li Z, Tian A. Exogenous activation of cannabinoid-2 receptor modulates TLR4/MMP9 expression in a spinal cord ischemia reperfusion rat model. J Neuroinflammation. 2020; 17: 101. PubMed: https://pubmed.ncbi.nlm.nih.gov/32248810/
  188. Bourke JA, Catherwood VJ, Nunnerley JL, Martin RA, Levack WMM, et al. Using cannabis for pain management after spinal cord injury: a qualitative study. Spinal Cord Ser Cases. 2019; 5: 82. PubMed: https://pubmed.ncbi.nlm.nih.gov/31632740/
  189. Huo J, Ma R, Chai X, Liang HJ, Jiang P, et al. Inhibiting a spinal cord signaling pathway protects against ischemia injury in rats. J Thorac Cardiovasc Surg. 2019; 157: 494-503. PubMed: https://pubmed.ncbi.nlm.nih.gov/30195603/
  190. Li H, Kong W, Chambers CR, Yu D, Ganea D, et al. The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cell Immunol. 2018; 329: 1-9. PubMed: https://pubmed.ncbi.nlm.nih.gov/29784129/
  191. Jing N, Fang B, Wang ZL, Ma H. Remote Ischemia Preconditioning Attenuates Blood-Spinal Cord Barrier Breakdown in Rats Undergoing Spinal Cord Ischemia Reperfusion Injury: Associated with Activation and Upregulation of CB1 and CB2 Receptors. Cell Physiol Biochem. 2017; 43: 2516-2524. PubMed: https://pubmed.ncbi.nlm.nih.gov/29130941/
  192. Grao-Castellote C, Torralba-Collados F, Gonzalez LM, Giner-Pascual M. Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience. Rev Neurol. 2017; 65: 295-302. PubMed: https://pubmed.ncbi.nlm.nih.gov/28929471/
  193. Mouhamed Y, Vishnyakov A, Qorri B, Sambi M, Frank SS, et al. Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug Healthc Patient Saf. 2018; 10: 45-66. PubMed: https://pubmed.ncbi.nlm.nih.gov/29928146/
  194. Abramovici H. Information for Health Care Professionals: Cannabis (Marihuana, Marijuana) and the Cannabinoids; Health Canada: Ottawa, ON, Canada, 2018.
  195. Jakubovski E, Pisarenko A, Fremer C, Haas M, May M, et al. The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. Front Psychiatry. 2020; 11: 575826. PubMed: https://pubmed.ncbi.nlm.nih.gov/33324255/
  196. Szejko N, Fichna JP, Safranow K, Dziuba T, Żekanowski C, et al. Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome. Front Genet. 2020; 11: 125. PubMed: https://pubmed.ncbi.nlm.nih.gov/32194619/
  197. Milosev LM, Psathakis N, Szejko N, Jakubovski E, Müller-Vahl KR. Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis Cannabinoid Res. 2019; 4: 265-274. PubMed: https://pubmed.ncbi.nlm.nih.gov/31872061/
  198. Avagliano C, Russo R, De Caro C, Cristiano C, La Rana G, et al. Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. Pharmacol Res. 2016; 113: 276-289. PubMed: https://pubmed.ncbi.nlm.nih.gov/27616549/
  199. Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One. 2012; 7: e41880. PubMed: https://pubmed.ncbi.nlm.nih.gov/22912680/
  200. Crupi R, Impellizzeri D, Cordaro M, Siracusa R, Casili G, et al. N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice. Mol Neurobiol. 2018; 55: 8455-8472. PubMed: https://pubmed.ncbi.nlm.nih.gov/29552727/
  201. Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014; 37: 41-44. PubMed: https://pubmed.ncbi.nlm.nih.gov/24614667/
  202. Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010; 51: 1413-1417. PubMed: https://pubmed.ncbi.nlm.nih.gov/20720046/
  203. Horne EA, Coy J, Swinney K, Fung S, Cherry AE, et al. Down regulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. Eur J Neurosci. 2013; 37: 429-440. PubMed: https://pubmed.ncbi.nlm.nih.gov/23167744/
  204. Augustin SM, Lovinger DM. Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System. ACS Chem Neurosci. 2018; 9: 2146-2161. PubMed: https://pubmed.ncbi.nlm.nih.gov/29400439/

Similar Articles

Recently Viewed

  • Environmental Factors Affecting the Concentration of DNA in Blood and Saliva Stains: A Review
    Divya Khorwal*, GK Mathur, Umema Ahmed and SS Daga Divya Khorwal*, GK Mathur, Umema Ahmed, SS Daga. Environmental Factors Affecting the Concentration of DNA in Blood and Saliva Stains: A Review. J Forensic Sci Res. 2024: doi: 10.29328/journal.jfsr.1001057; 8: 009-015
  • Why Down-managing Backlog Forensic DNA Case Entries Matters
    JH Smith* and JS Horne JH Smith*, JS Horne. Why Down-managing Backlog Forensic DNA Case Entries Matters. J Forensic Sci Res. 2024: doi: 10.29328/journal.jfsr.1001056; 8: 001-008
  • Scintigraphic non-invasive diagnosis of amyloid cardiomyopathy
    Laroussi Mohamed-Salem*, Tomás E Rodríguez-Locarno, Tatiana Moreno-Monsalve, Isabel Castellón-Sánchez, José F Contreras-Gutiérrez and Antonia Claver-Valderas Laroussi Mohamed-Salem*,Tomás E Rodríguez-Locarno,Tatiana Moreno-Monsalve,Isabel Castellón-Sánchez,José F Contreras-Gutiérrez ,Antonia Claver-Valderas. Scintigraphic non-invasive diagnosis of amyloid cardiomyopathy. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001058; 4: 156-158
  • Anomalies of coronary artery origin: About two cases
    Dioum M*, Sarr EM, Manga S, Mingou JS, Diack A, Diop AD, Bindia D, Diagne PA, Sarr AN and Diop IB Dioum M*,Sarr EM,Manga S,Mingou JS,Diack A,Diop AD,Bindia D,Diagne PA,Sarr AN,Diop IB. Anomalies of coronary artery origin: About two cases. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001051; 4: 117-119
  • Late discover of a traumatic cardiac injury: Case report
    Benlafqih C, Bouhdadi H*, Bakkali A, Rhissassi J, Sayah R and Laaroussi M Benlafqih C,Bouhdadi H*,Bakkali A,Rhissassi J,Sayah R,Laaroussi M. Late discover of a traumatic cardiac injury: Case report. J Cardiol Cardiovasc Med. 2019: doi: 10.29328/journal.jccm.1001048; 4: 100-102

Read More

Most Viewed

Read More

Contact

Editorial Office Emails:

info@hspioa.org

amelia.sandra@hspioa.us

elena.maya@hspioa.us

Select by Volume & Issue

Submit Manuscript Information for Authors Advisory Board Rss Feed Articles Rss Feed

Most Viewed Keywords

University/Institution

Select and search by University/Institution.

Articles by Country

Select and search by country to get related articles.

Testmonials

I would like to thank JPRA for taking this decision. I understand the effort it represents for you. I'm truly happy to have the paper published in JPRA. And I'll certainly consider JPRA for my next publications as I was satisfied of the service provided, the efficiency and promptness of the interactions we had.

Emmanuel BUSATO

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

Elizabeth Awoyesuku

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Elisabeth H Wiig

Archives of Vascular Medicine is one of the top class journal for vascular medicine with highly interesting topics. You did a professional and great Job!

Elias Noory

Thank you very much. I think the review process and all of what concerns the administration of the publication concerning our paper has been excellent. The nice and quick answers have been very good I think.

Doris Nilsson

Journal of Pulmonary and Respiratory Research is good journal for respiratory research purposes. It takes 2-3 weeks maximum for review of the manuscript to get published and any corrections to be made in the manuscript. It needs good articles and studies to get publish in the respiratory medicine. I am really glad that this journal editors helped me to get my case report published.

Divya Khanduja

Thanks you and your colleague for the great help for our publication. You always provide prompt responses and high quality of service. I am so happy to have you working with me. Thanks again!

Diana (Ding) Dai

Service and process were excellent as was the “look” of the article when published.

Deane Waldman

Great, thank you! It was very efficient working w/ your group. Very thorough reviews (i.e., plagiarism, peer, etc.). Would certainly recommend that future authors consider working w/ your group.

David W Brett

Your services are very good

Chukwuka Ireju Onyinye

I very much appreciate the humanitarian services provided in my stead by this journal/publisher. It exhibits total absence of editorial impertinence. As an Author, I have been guided to have a fruitful experience. The editorial care is highly commendable.

Chrysanthus Chukwuma

"An amazing experience with the Journal of Advanced Pediatrics and Child Health. Very fast blind review with pertinent corrections and suggestions. I highly recommand both the journal and the editor."

Chaimae Khairoun

The submission is very easy and the time from submission to response from the reviewers is short. Correspondence with the journal is nice and rapid.

Catrin Henriksson

The Clinical Journal of Obstetrics and Gynecology is an open access journal focused on scientific knowledge publication with emphasis laid on the fields of Gynecology and Obstetrics. Their services toward us have been encouraging through their kindness and respect. Great consideration has been given to us as young budding researchers and we are very grateful for this.

Carole Assontsa

During the process your positive communication, prompt feedback and professional approach is very highly appreciated. We would like to thank you very much for your support.

Can Vuran

I do appreciate for your service including submission, analysis, review, editorial and publishing process. I believe these esteemed journal enlighten the science with its high-quality personel.

Bora Uysal

I am very much pleased with the fast track publication by your reputed journal's editorial team. It is really helpful for researchers like me from developing nations. I strongly recommend your journal for publication.

Badri Kumar Gupta

It has been a fabulous journey writing articles for your journal because of the encouragement you people provide for writers from developing nations like India. Kindly continue the same. Looking forward for a long term association.

Badareesh Lakshminarayana

Many thanks for publishing my article in your great journal and the friendly and hassle-free publication process, the constructive peer-review, the regular feedback system, and the Quick response to any queries.

Azab Elsayed Azab

I would like to thank this journal for publishing my Research Article. Something I really appreciate about this journal is, they did not take much time from the day of Submission to the publishing date. Looking forward to have more publications in future.

Ayush Chandra

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ayokunle Dada

Your service is very good and fast reply, also your service understand our situation and support us to publication our articles.

Ayman M Abu Mustafa

Really good service with prompt response. Looking forward to having long lasting relationship with your journal

Avishek Bagchi

Your service is excellent. Processing and editing were very fast. I hope to publish more of my works in your journal.

Ausraful Islam

I wanna to thank Clinical Journal of Nursing Care and Practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Atsedemariam Andualem

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Asafo Jones

I hope to ability to make some new investigation and publish in Your Company in future.

Artur Stopyra

I like the quality of the print & overall service. The paper looks quite impressive. Hope this will attract interested readers. All of you have our best wishes for continued success.

Arshad Khan

Your big support from researchers around the world is the best appreciation from your scientific teams. We believe that there should be no barrier in science and you make it real and this motto come true.

Arefhosseinir Rafi

Your journal co-operation is very appreciable and motivational. I am really thankful to your journal and team members for the motivation and collaboration to publish my work.

Assistant Professor, UCLAS Uttaranchal University, Dehradun, India

Archna Dhasmana

I am glad to submit the article to Heighten Science Publications as it has a very smooth and fast peer-review process, which enables the researchers to communicate their work on time.

Anupam M

This is to specify that I have had an extensive and detailed interaction with the Editorial team of Annals of Clinical Gastroenterology and Hepatology, USA, lasting over a significant period of time. My interaction has been extremely pleasant, especially with Ms Allie Smith, as I find the communication quite inspiring and crystal clear. The attitude of aforesaid individuals is quite helpful and guiding in pertinent instances. It has been a commemorative journey so far working with the Journal and I hope that the symbiosis will continue, evolve and flourish in the forthcoming years. I wish the journal, related personnel and aforementioned individuals a fruitful, successful run.

New Delhi, India

Anubha Bajaj

We appreciate the fact that you decided to give us full waiver for the applicable charges and approve the final version. You did an excellent job preparing the PDF version. Of course we will consider your magazine for our future submissions and we will pay the applicable fees then.

Anna Dionysopoulou

''Co-operation of Archives of Surgery and Clinical Research journal is appreciable. I'm impressed at the promptness of the publishing staff and the professionalism displayed. Thank you very much for your support, help and encouragement.''

Anıl Gokce

Congratulations for the excellence of your journal and high quality of its publications.

Angel MARTIN CASTELLANOS

The service from the journal staff has been excellent.

Andy Smith

I was very pleased with the quick editorial process. We are sure that our paper will have great visibility, among other things due to its open access. We believe in science accessible to all.

Anderson Fernando de Souza

It was a great experience publishing through JCICM. The article has reached out to several institutions. Appreciate your professional work. Hope to work with you again

Anas Wardeh

Publishing an article is a long process, but working with your publication department made things go smoothly, even though the process took exactly 5 months from the time of submitting the article till the time I have favourable response, the missing part is the peer review details, which is essential in self auditing and future improvement, overall experience was excellent giving your understanding of the situation of lack of financial institution support.

Anas Diab

I think that Heighpubs very good. You are very helpful. Thank you for everything.

Ana Ribeiro

Regarding to be services, we note that are work with high standards of professionalism translated into quick response, efficiency which makes communication accessible. Furthermore, I believe to be much inviting for the submission of future works for publication purposes.

Amélia João Alice Nkutxi

I would like to mention that I had a wonderful experience working with HSPI. The whole process right from manuscript submission to peer review till the publication of the article was very prompt & efficient. I wish you good luck for the future.

Amarjeet Gambhir

Once I submitted the manuscript, the response time of the reviewers was very fast. The fine-tuning of the galley proof was likewise prompt. I believe the journal provide a valuable outlet to disseminate physical rehabilitation scientific knowledge to the clinical community. Respectfully. Dr. Alon

Alon

We really appreciate and thanks the full waiver you provide for our article. We happy to publish our paper in your journal. Thank you very much for your good support and services.

Ali Abusafia

It was a real pleasure working with your team. The review was done fast, and it was very clear, the editing was flawless, the article was published quickly compared to other journals, and everyone was understanding and helpful. I will gladly recommend this journal to my acquaintances in academia.

Alexandra Cozma

To the editorial team at HSPI and the Journal of Clinical Nephrology: Thank you so much for your hard work and collaboration in bringing our article to life. Your staff was responsive, flexible, and communicative and made the process smooth and easy. Thank you!

Alejandro Munoz

Dear colleagues! I am satisfied with our cooperation with you. Your service is at a high level. I hope for a future relationship. Let me know if I can get a paper version of the magazine with my articles from you. I see them on the Internet.

Aksenov V.V

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ajite Kayode

I want to thank you for our collaboration. You were fast and effective with a positive spirit of teamwork. I am truly excited from our collaboration. You were like always fast, efficient and accurate. I hope that in the near future we will collaborate again.

Aikaterini Solomou

In my opinion, you provide a very fast and practical service.

Ahmet Eroglu

Great, We are too comfortable with the process including the peer review process and quality. But, the journal should be indexed in different databases such scopus.

Afework Edmealem

We really appreciate your efforts towards our article, the professional way you handle our request for exemption from charges. It was a great honor for us to publish in your magazine.

Achraf elbakkaly

I really liked the ease of submitting my manuscript in the HSPI journal. Further, the peer review was timely completed and I was communicated the final decision on my manuscript within 10 days of submission which is really appreciable. I strongly recommend all the scientists and researchers to submit their work in this journal”

Abu Bashar

My candid opinion is that the service you render is second to none. My favourite part is the prompt response to issue, really i value that.

Abiodun Akanbi Adeogun

Thank you very much for accepting our manuscript in your journal “International Journal of Clinical Virology”. We are very thankful to the esteemed team for timely response and quick review process. The editorial team of International Journal of Clinical Virology is too cooperative and well-mannered during the publication process. We are hopeful to publish many quality papers in your journal and I suggest the International Journal of Clinical Virology to all of my colleagues, researchers and friends to publish their research here.

Abdul Baset

I, Muhammad Sarwar Khan, am serving as Editor on Archives of Biotechnology and Biomedicine (ABB). I submitted an editorial titled, 'Edible vaccines to combat Infectious Bursal Disease of poultry' for publication in ABB. After submitting the manuscript; the services rendered by the management and technical personnel to handle and process the manuscript were marvelous. Plagiarism report was shared with me with complements before reviewers' comments, All steps including article processing and service charges were well taken care of keeping in view the author's interest/preference. All together, it was an encouraging and wonderful experience working with ABB personnel.

University of Agriculture, Pakistan

Muhammad Sarwar Khan

Your journal has accomplished its intended mission of providing very effective and efficient goals in dealing with submissions, conducting the reviewing process and in publishing accepted manuscripts in a timely manner. Keep up the great work and services that you provide.

University of Jacqmar, Inc., USA

John St. Cyr

I am to express my view that Heighten Science Publications are reliable quick even after peer review process. I hope and wish the publications will go a long way in disseminating science to many interested in scientific research.

College of Fisheries, CAU(I), Tripura, India

Ajit Kumar Roy

The Journal Clinical Nephrology provides a good opportunity for readers to stay updated in the field of clinical nephrology. Additionally - it provides a good opportunity for authors to publish their work. 1. Publication of the accepted manuscripts is sufficiently rapid. 2. The trust factor between the journal and me, as an author, is very important and well preserved. 3. Peer review process very rapid and effective.

Assaf Harofeh Medical Center, Israel

Leonid Feldman

In 2017, I submitted a manuscript to the journal Archives of Biotechnology and Biomedicine belonging to Heighten Science Publications Corporation. Within one week I already received the response from the editor. All processing steps were really fast so in terms of a speedy publication I can particularly recommend the journal Archives of Biotechnology and Biomedicine. The responsible contact person of the journal was always available, which gives a trustworthy impression to the author. Also the peer review process was clear and constructive. So from my experience with Heighten Science Publications Corporation I can recommend publishing there.

University of Tubingen, Germany

Yvonne Mast

We thank to the heighten science family, who speed up the publication of our article and provide every support.

Mehmet Besir

The services of the journal were excellent. The most important thing for an author is the speed of the peer review which was really fast here. They returned in a few days and immediately replied all of my questions. I want to refer this platform to all scholars. Many thanks.

Eastern Mediterranean University, Cyprus

Zehra Guchan TOPCU

Thank you for your attitude and support. I am sincerely grateful to you and the entire staff of the magazine for the high professionalism and fast quality work. Thank you very much!

USA

Igor Klepikov

Thank you and your company for effective support of authors which are very much dependable on the funds gambling for science in the different countries of our huge and unpredictable world. We are doing our work and should rely on a teams like Galley Proof-HSPC. Great success to all of you for the 2019th! Be well all the year long.

Russia

Victor V Apollonov

The editorial process was quickly done. The galley proof was sent within a week after being accepted for publication. The editorial team was very helpful and responded promptly.

India

Rohit Kulshrestha

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

University of Port Harcourt Teaching Hospital, Nigeria

Dr. Elizabeth A Awoyesuku

"It was a pleasure to work with the editorial team of the journal on the submission of the manuscript. The team was professional, fast, and to the point".

NC A&T State University, USA

Moran Sciamama-Saghiv

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ekiti State University Teaching Hospital, Nigeria

Ayokunle Dada

I am delighted and satisfied with. Heighten Science Publications as my manuscript was thoroughly assessed and published on time without delay. Keep up the good work.

Ido-Ekiti/Afe Babalola University, Nigeria

Dr. Shuaib Kayode Aremu

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ekiti State University, Nigeria

Adebukola Ajite

I wanna to thank clinical journal of nursing care and practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Wollo University, Ethiopia

Atsedemariam Andualem

We appreciate your approach to scholars and will encourage you to collaborate with your organization, which includes interesting and different medical journals. With the best wishes of success, creativity and joy in life, prosperity in the medical field.

Ivano- Frankivsk National Medical University, Ukraine

Nataliya Kitsera

Thank you very much for your support and encouragement. I am truly impressed by your tolerance and support. Thank you very much

Diaverum: PADC, Jeddah, Saudi Arabia

Nasrulla Abutaleb

You are such a nice person. Your journal co-operation is very appreciable and motivational.

Department of Biotechnology, Uttaranchal college of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India

Archna Dhasmana

“Mobile apps and wearable technology are becoming ubiquitous in our environment. Their integration with healthcare delivery is just beginning to take shape. The early results are promising and the possibilities great."

BS, PharmD., MBA, CPHIMS, FHIMSS, Adjunct Professor, Global Healthcare Management, MCPHS University, Chief Strategy Offi cer, MedicaSoft, Senior Advisor, National Health IT (NHIT) Collaborative for Underserved, New York HIMSS, National Liaison, Health 2.0 Boston, Past Chair, Chair Innovation, USA

Helen Figge

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Ph.D, Boston University Department of Communication Sciences and Disorders and Knowledge Research Institute, Inc., 2131 Reflection Bay Drive, Arlington, Texas 76013, USA

Elisabeth H. Wiig

The service is nice and the time of processing the application is fast.

Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong

Long Ching

Your service is very good and fast reply, Also your service understand our situation and support us to publication our articles.

Palestine College of Nursing, Khan Younis, Gaza Strip, Palestine

Ayman M Abu Mustafa

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Department of Agricultural Economics, Agribusiness and Extension, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Akowuah Jones Asafo

View More

Related Journals

Help ?